Alzheimer's Disease: Defusing The Bomb By 2025

The number of drug candidates in development for Alzheimer's is at its highest-ever level and despite the lack of success to date, biopharma companies continue to believe the potential rewards are worth the risk. As R&D in the field accelerates, therapies that treat not only symptoms of the disease but also slow its progression are expected to arrive sooner rather than later.

"This is a time bomb." These words could refer to any number of perilous global issues currently grabbing headlines. We could be talking about global warming, China's economic downturn, fossil fuels, Ebola or terrorism – but we're not. These are the words used by Gill Morgan, chair of NHS Providers, the UK's National Health Service trade association for acute, ambulance, community and mental health services, to describe Alzheimer's disease.

Alzheimer's disease, an irreversible, progressive neurodegenerative disease, is the most common cause of dementia among the elderly, accounting for between...

More from Growth

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.